相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Real-World Safety and Efficacy of Consolidation Durvalumab After Chemoradiation Therapy for Stage III Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis
Yu Wang et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2022)
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
David R. Spigel et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer
Hiroshi Mayahara et al.
RADIATION ONCOLOGY (2022)
Durvalumab after chemoradiotherapy for locally advanced non-small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice
Takaya Yamamoto et al.
BMC CANCER (2022)
CLINICAL INVESTIGATION Prognostic and Predictive Role of PD-L1 Expression in Stage III Non-small Cell Lung Cancer Treated With Definitive Chemoradiation and Adjuvant Durvalumab
Kamya Sankar et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2022)
Chemoradiation followed by adjuvant durvalumab in stage III non-small cell lung cancer: Real-world comparison of treatment outcomes to historical controls treated with chemoradiation alone
Akram Saad et al.
THORACIC CANCER (2022)
Predictive value of post-treatment C-reactive protein-to-albumin ratio in locally advanced non-small cell lung cancer patients receiving durvalumab after chemoradiotherapy
Taisuke Araki et al.
THORACIC CANCER (2022)
Immunotherapy After Chemotherapy and Radiation for Clinical Stage III Lung Cancer
Matthew D. Pichert et al.
JAMA NETWORK OPEN (2022)
Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab
Yufei Liu et al.
JAMA NETWORK OPEN (2022)
Impact of radiation dose to the immune cells in unresectable or stage III non-small cell lung cancer in the durvalumab era
Neal S. McCall et al.
RADIOTHERAPY AND ONCOLOGY (2022)
Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: A real-world multicentre study
Antoine Desilets et al.
EUROPEAN JOURNAL OF CANCER (2021)
Effect of durvalumab on local control after concurrent chemoradiotherapy for locally advanced non-small cell lung cancer in comparison with chemoradiotherapy alone
Takanori Abe et al.
THORACIC CANCER (2021)
Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy
Kartik Sehgal et al.
JAMA NETWORK OPEN (2021)
Tumor PD-L1 expression is associated with outcomes in stage 3 NSCLC patients treated with consolidation durvalumab
Khalid Jazieh et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2021)
Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC
Jhanelle E. Gray et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with checkpoint inhibitors
Ali Raza Khaki et al.
CANCER (2020)
Performance status and end-of-life care among adults with non-small cell lung cancer receiving immune checkpoint inhibitors
Laura A. Petrillo et al.
CANCER (2020)
Preoperative platelet-lymphocyte ratio is a superior prognostic biomarker to other systemic inflammatory response markers in non-small cell lung cancer
Qing Huang et al.
MEDICINE (2020)
Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer
Hyun Ae Jung et al.
LUNG CANCER (2020)
Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab
Alex Friedlaender et al.
ACTA ONCOLOGICA (2020)
A case report of a patient with bulky uterine cervical neoplasm who achieved complete response with intentional internal high-dose policy high-dose-rate interstitial brachytherapy
Tairo Kashihara et al.
MEDICINE (2020)
Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP)
Martin Faehling et al.
LUNG CANCER (2020)
Efficacy and safety of immune checkpoint inhibitor consolidation after chemoradiation in patients of Asian ethnicity with unresectable stageIIInon-small cell lung cancer: Chinese multicenter report and literature review
Tao Zhang et al.
THORACIC CANCER (2020)
Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer
Kazue Yoneda et al.
BRITISH JOURNAL OF CANCER (2019)
Interstitial Lung Abnormality: Recognition and Perspectives
Hiroto Hatabu et al.
RADIOLOGY (2019)
Prognostic biomarkers in stage IV non-small cell lung cancer (NSCLC): neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI)
Hiren Mandaliya et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2019)
ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer
Ursula Nestle et al.
RADIOTHERAPY AND ONCOLOGY (2018)
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab
Stefan Diem et al.
LUNG CANCER (2017)
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Investigation of the freely available easy-to-use software 'EZR' for medical statistics
Y. Kanda
BONE MARROW TRANSPLANTATION (2013)
Association of Computed Tomography-detected Pulmonary Interstitial Changes with Severe Radiation Pneumonitis for Patients Treated with Thoracic Radiotherapy
Naoko Sanuki et al.
JOURNAL OF RADIATION RESEARCH (2012)
分享论文
